Court Grants Delay in Lawsuit Challenging FDA's Mint Ban

Feb.25
Court Grants Delay in Lawsuit Challenging FDA's Mint Ban
Federal judge Haywood S. Gilliam halts lawsuit challenging FDA's delay in implementing mint tobacco ban until mid-August.

According to Tobacco Reporter, on February 24, United States Federal District Judge Haywood S. Gilliam issued a two-page order granting a joint request from the government defendants and public health advocates to postpone the litigation proceedings until mid-August. The lawsuit, brought by anti-tobacco organizations, aims to challenge the U.S. FDA's decision to delay implementing a ban on mint-flavored cigarettes. The judge suspended the case in response to actions taken by the Trump administration.


Judge Haywood S. Gilliam of the Northern District Court of California has ordered a temporary halt to the proceedings between the African American Tobacco Control Leadership Council and the FDA. The case involves whether the FDA acted lawfully in delaying the final regulation proposed by the Biden administration to ban mint-flavored cigarettes from the market. Both parties jointly submitted a proposal to postpone the case on February 18. At the end of January, the FDA withdrew proposed rules regarding banning mint as a characteristic flavor in cigarettes and banning all characteristic flavors in cigars.


Troutman Pepper Locke law firm wrote in its tobacco law blog.


The recent repeal of the federal flavor ban clearly indicates that the Trump administration has taken a less aggressive stance on rulemaking than the Biden administration.


However, the reply from the Information and Regulatory Affairs Office did not provide detailed explanations for the withdrawal. Nevertheless, several comments submitted during the public comment period for each proposed rule have thoroughly outlined ample reasons for the withdrawal of the proposal.


Regarding the ban on mint cigarettes, industry insiders believe that despite proposed prohibition measures, consumer demand for mint cigarettes will lead to a widespread illicit market.


Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.

Poland’s Disposable Vape Sales Drop 22%, Prices Set to Triple
Poland’s Disposable Vape Sales Drop 22%, Prices Set to Triple
Poland’s new excise tax on tobacco products is set to take effect in July 2025, imposing a levy of 40 zloty (around $10) per disposable e-cigarette containing e-liquid. Although the law has yet to be implemented, the market is already seeing a decline, with disposable vape sales in Q1 2025 down 22% yoy. Once the tax is enforced, prices are expected to rise from around $5 to nearly $13 per unit.
May.19 by 2FIRSTS.ai
BAT 2024 Results Summary: New Business Earnings Growth,Despite 5.2% Revenue Decline
BAT 2024 Results Summary: New Business Earnings Growth,Despite 5.2% Revenue Decline
Despite a 5.2% drop in reported revenue in 2024, BAT's organic revenue increased 1.3%, with new tobacco business profits.
Apr.18 by 2FIRSTS.ai
RELX Technology Q1 2025 Financial Report: Revenue Rises 46.5% YoY to $110 Million, Slips 0.6% from Previous Quarter
RELX Technology Q1 2025 Financial Report: Revenue Rises 46.5% YoY to $110 Million, Slips 0.6% from Previous Quarter
RELX Technology reported net revenue of RMB 810 million (US $110 million) for Q1 2025, down 0.6% quarter-over-quarter but up 46.5% year-over-year. On a non-GAAP basis, adjusted net profit for the quarter was RMB 250 million (US $34.6 million), a 0.2% decrease from the previous quarter and a 21.0% increase from a year earlier.
May.16 by 2FIRSTS.ai
German Court: ELFPRO Infringed ELFBAR Trademark; Offender to Cease Operations
German Court: ELFPRO Infringed ELFBAR Trademark; Offender to Cease Operations
The Düsseldorf Regional Court ruled that the use of "ELFPRO" infringed on ELFBAR's trademark. The court supported iMiracle’s claims during the interim injunction phase. The infringing party plans to cease operations under legal pressure.
Apr.29 by 2FIRSTS.ai
Lib Dem MPs call for tax cuts on heated tobacco products
Lib Dem MPs call for tax cuts on heated tobacco products
LDP lawmaker Tanaka calls for tax breaks on heated tobacco products, government remains skeptical on harm reduction benefits.
Apr.17 by 2FIRSTS.ai
FDA Embraces AI: Generative System to Be Fully Operational by June's End
FDA Embraces AI: Generative System to Be Fully Operational by June's End
FDA plans to fully integrate a generative AI system across its centers by June 30, 2025. This follows the successful completion of an initial pilot, marking a shift in the agency's approach to regulatory processes. The AI tools are expected to streamline the drug approval process, which typically takes six to ten months, by reducing time spent on repetitive tasks.
May.09 by 2FIRSTS.ai